We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Bristol Myers Squibb (BMS) said that its late-stage trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) did not meet its goal of improving overall survival compared with standard-of-care treatment in certain patients with untreated unresectable or metastatic urothelial cancer. Read More
Acella Pharmaceuticals is facing a potential class action lawsuit in a federal court in Georgia that claims its NP Thyroid hormone replacement drug is “worthless” and left one patient with “hypothyroidism, including hair loss, extreme fatigue, painful sensitivity to temperature changes and debilitating hives.” Read More
The novel combination of albuterol and budesonide in AstraZeneca’s PT027 reduced the risk of severe asthma flare-ups by 27 percent in patients with moderate-to-severe asthma, according to results from a late-stage study. Read More
The FDA has approved Eli Lilly’s Mounjaro (tirzepatide) injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The approval marks the first new class of drugs for type 2 diabetes in 10 years. Read More
A two-week course of Gilead’s investigational HIV-1 drug, lenacapavir, followed by twice-yearly injections, almost completely suppressed viral load in patients with multidrug-resistant infections. Read More
The FDA issued over-the-counter (OTC) drug and cosmetic manufacturer Allure Labs a four-observation Form 483 following a November to December 2021 inspection of its Hayward, Calif., facility, noting procedural lapses and possible underreporting of deviations, nonconformances and out-of-specification (OOS) events. Read More